Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to almost 2.5 times the number of adults currently living with diabetes. There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes. Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54,728,518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456,906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706). Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cagrilintide is a long-acting amylin analogue [169,164].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [164]
In the citing paper
“Amylin may promote weight reduction and increase sensitivity to leptin in patients with obesity.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [164]
In the citing paper
“Bariatric surgery is the most effective antiobesity management strategy characterized by average of 30–40% weight loss, but it comes at a cost of irreversibility, surgery-related complications and considerable percentage of late complications [2].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [2]
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“semaglutide [74] and dulaglutide [126].”
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Regulation of Lipolysis in Adipocytes
Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul, H. S. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093734 · Cited by 1,021
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 2×
“advanced dual GIP and GLP-1 receptor agonist has demonstrated larger weight reducing properties in clinical trials compared to dulaglutide [32].”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Research works printed but not linked: 19
- van Rijswijk A-S, 2021, Obes Surg
- Kang JH, 2017, Medicine (Baltimore), 96
- Kelly T, 1986, Int J Obes, 10, 7
- Cawley J, 2012, J Health Econ, 42, S90
- Moonschi FH, 2018, Acta Diabetol, 10
- Mathiesen DS, 2019, Int J Mol Sci, 21
- Fu W, 2013, Front Aging Neurosci, 13, 5
- Griffith DA, 2020, bioRxiv
- Lau J, 2015, J Med Chem, 155
- Wilding JPH, 2021, N Engl J Med, 384, NEJMoa2032183
- CT 868 - AdisInsight [Internet]. [cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800053575
- 2018, Mol Metab, 33, 3
- Ingelheim B, Pharma Z Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to phase 2 clinical testing in obesity/diabetes [Internet]. boehringer-ingelheim.us. [cited 2021 Feb 5]. Available from: https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi
- BI 456906 - AdisInsight [Internet]. [cited 2021 Feb 16]. Available from: https://adisinsight.springer.com/drugs/800049709
- 2019, Hepatology, 70, 1
- HM 15211 - AdisInsight [Internet]. [cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800049366
- Jph W,SJ, 2021, Obes Rev Off J Int Assoc Study Obes, 22
- Jp W, 2016, Diabetes Obes Metab, 18
- 2021, Cell Rep Med, 30, 100263
Cited by
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Excess body weight: Novel insights into its roles in obesity comorbidities
Zhang, X., Ha, S., Lau, H. C.-H., & Yu, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.008 · Cited by 228
Metadata
- Authors
- Jepsen, M. M., & Christensen, M. B.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Christensen, Mikkel B.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2021-07-03
- Volume
- 26
- Issue
- 3
- Pages
- 231-243
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W3176790398
- Cited by
- 96
- References
- 65
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 20 · 2023: 29 · 2022: 11 · 2021: 5
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Emerging Drugs (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, GLP-1 receptor agonists, anti-obesity drugs, semaglutide, tirzepatide, oxyntomodulin, amylin, glucagon, energy balance, drug development, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. https://app.cochat.ai/papers/10.1080/14728214.2021.1947240
- The paper
- Jepsen, M. M., & Christensen, M. B. (2021). Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2021.1947240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.